abs257.txt	purpose		her2	+	breast	cancer	(bc)	is	an	aggressive	subtype	with	high	rates	ofbrain	metastases	(bcbm)	two-thirds	of	bcbm	demonstrate	activation	thepi3k/mtor	pathway	driving	resistance	to	anti-her2	therapy	this	phase	ii	studyevaluated	everolimus	(e)	a	brain-permeable	mtor	inhibitor	trastuzumab	(t)	andvinorelbine	(v)	in	patients	and	methods	eligible	had	progressive	the	primaryendpoint	was	intracranial	response	rate	(rr)	secondary	objectives	were	cnsclinical	benefit	(cbr)	extracranial	rr	time	progression	(ttp)	overallsurvival	(os)	targeted	sequencing	tumors	from	enrolled	atwo-stage	design	distinguished	5%	versus	20%	results	32	evaluable	for	toxicity	26	efficacy	intracranialrr	4%	(1	pr)	cns	cbr	at	6	mos	27%	3	65%	median	ttpwas	9	(95%	ci	2	2-5)	os	12	0	6-20	2)	grade	3-4toxicities	included	neutropenia	(41%)	anemia	(16%)	stomatitis	mutations	tp53	pik3ca	common	pi3k/mtorpathway	not	associated	erbb2	amplification	higher	bcbmcompared	primary	bc	trended	towardworse	conclusion	while	etv	low	one-third	achieved	ttp/os	similar	historical	control	no	newtoxicity	signals	observed	further	analysis	genomic	underpinnings	ofbcbm	identify	tractable	prognostic	and/or	predictive	biomarkers	warranted	clinical	trial	(nct01305941)
